Trial Profile

A Randomized, Open-label, Phase III Study of ESG401 Versus Investigator's Choice Chemotherapy as First-line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ESG 401 (Primary) ; Capecitabine; Carboplatin; Eribulin; Paclitaxel; Taxanes
Indications Triple negative breast cancer
Focus Therapeutic Use
Sponsors Qilu Pharmaceutical; Shanghai Escugen Biotechnology

14 May 2025 Planned initiation date changed from 1 Feb 2025 to 1 Sep 2025.
29 Jan 2025 According to Vincerx Pharma media release, this study garnered Breakthrough Designation from China National Medical Products Administration (NMPA) on November 6, 2024.
18 Dec 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com